Exicure downgraded by Chardan Capital Markets with a new price target

12/13/21 8:43:28 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Chardan Capital Markets downgraded Exicure from Buy to Neutral and set a new price target of $0.40 from $2.25 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XCUR

Date	Price Target	Rating	Analyst
12/13/2021	$2.25 → $0.40	Buy → Neutral	Chardan Capital Markets
11/23/2021	$7.00 → $2.25	Buy	Chardan Capital